Results 111 to 120 of about 5,458 (150)

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. [PDF]

Future Oncol
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, SENTRY investigators.   +10 more
europepmc   +1 more source

Medinfo mit neuer Adresse

Archivalia, 2019
openaire   +2 more sources

Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort. [PDF]

Medicine (Baltimore)
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kuroki K, Haraguchi T, Yamada S, Sangen R, Kiyosawa J, Saito A, Iguchi M, Nakahashi T, Kasamaki Y, Fukuda A, Kanda T, Okuro M.   +15 more
europepmc   +1 more source

medinfo wird 7 Jahre

netbib, 2011
openaire   +1 more source

Development and preclinical characterization of AMG 329: a human antibody neutralizing FLT3 ligand. [PDF]

MAbs
Lau-Kilby A, Gunsior M, Bartczak A, Chyou S, Hester J, Sims D, Xiao X, Pavlik P, Chen Y, Casey KA, Zerrouki K, Wang Q, Borrok MJ, Hansen AM, Rees WA.   +14 more
europepmc   +1 more source

A Call to Action. [PDF]

Yearb Med Inform, 2019
Lehmann CU, President of the International Medical Informatics Association.   +1 more
europepmc   +1 more source

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. [PDF]

Am J Clin Dermatol
Marinkovich MP, Paller AS, Guide SV, Gonzalez ME, Lucky AW, Bağcı IS, Agostini B, Fitzgerald K, Chen S, Chen H, Conner MM, Krishnan SM.   +11 more
europepmc   +1 more source

Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01. [PDF]

Transl Psychiatry
Stamatis CA, Heusser AC, Simon TJ, Ala'ilima T, Kollins SH.   +4 more
europepmc   +1 more source

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. [PDF]

Future Oncol
Bazhenova L, Kim DW, Cho BC, Goel S, Heist R, Werner TL, Eaton KD, Wang JS, Pant S, Adkins DR, Blakely CM, Yan X, Neuteboom S, Christensen JG, Chao R, Bauer T.   +15 more
europepmc   +1 more source